Metformin is the most commonly prescribed drug for type 2 diabetes mellitus. In recent years,
in addition to glucose lowering, several studies have presented evidence suggesting some …

Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of plasminogen
activators (PAs) and is therefore an important inhibitor of the plasminogen/plasmin system …

Metformin is an oral hypoglycemic agent which is most widely used as first-line therapy for
type 2 diabetes. Metformin improves hyperglycemia by suppressing hepatic glucose …

Considerable efforts have been made since the 1950s to better understand the cellular and
molecular mechanisms of action of metformin, a potent antihyperglycaemic agent now …

Patients with diabetes mellitus are at increased risk of cancer development. Metformin is a
well-established, effective agent for the management of type 2 diabetes mellitus …

Metformin is a biguanide drug widely used as the initial treatment of type 2 diabetes. Despite
its widespread use, its precise mechanisms of action remain incompletely characterised. Its …

Background Metformin is an oral anti‐hyperglycemic agent that has been shown to reduce
total mortality compared to other anti‐hyperglycemic agents, in the treatment of type 2 …

Obesity is associated with an increased risk of developing breast cancer and is also
associated with worse clinical prognosis. The mechanistic link between obesity and breast …

The identification of small subpopulations of cancer stem cells (CSCs) from blood
mononuclear cells in human acute myeloid leukemia (AML) in 1997 was a landmark …

Plasminogen activator inhibitor 1 (PAI-1) is a member of the serine protease inhibitor
(serpin) superfamily. PAI-1 is the principal inhibitor of the plasminogen activators, tissue …